Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Cancer Res. 2021 Sep 30;81(23):6018–6028. doi: 10.1158/0008-5472.CAN-21-0030

Figure 5. DAC/ENT combination treatment targeted SALL4 negative cancer cells in culture.

Figure 5.

(A) Schema of DAC and ENT combination treatment of H1299 or H661 cells. (B) Relative cell viability and IC50 of DMSO or DAC pre-treated H661 cells following ENT therapy. (C) Relative cell viability and IC50 of DMSO or DAC pre-treated H1299 cells following ENT therapy. (D) Schema of experiment design in (E&F). (E) Protein level of SALL4 in shNC or shSALL4 stable expressing H1299 cells after 5 days treatment of DMSO or DAC. (F) Percentage of IC50 against ENT for indicated H1299 cells, IC50 of DMSO treated group was used as normalization control. (G) Schema of experiment design in (H&I). (H) Protein level of SALL4 in H1299 cells after 7, 14, or 21 days of DMSO or DAC treatment. (I) Percentage of IC50 against ENT for indicated time point of H1299 cells, IC50 of DMSO treated group was used as normalization control. n.s. means P>0.05, *P<0.05, **P<0.01, ***P<0.001, N=3.